Pharmaceuticals company Akums Drugs & Pharmaceuticals announced Q3FY25 results Total Income at Rs 10,250 million, decline of 6.1% YoY, decline of 2.1% QoQ. Adjusted EBITDA of Rs 1,359 million, up 12.1% YoY, up 0.9% QoQ. Adj EBITDA Margin at 13.3%, Adj PAT Margin at 6.5%. Adjusted PAT of Rs 663 million, up 15.2% YoY, decline of 0.5% QoQ. Sanjeev Jain, Managing Director, said: “Q3 was an exciting quarter for the company. With our focus on establishing Akums' global CDMO footprint, we took a significant step by securing a EUR 200 million contract. The contract involves manufacture and supply of products to be sold in European markets. We believe this is the first of many partnerships we will undertake to serve the European market in the years to come.” Sandeep Jain, Managing Director, said: “We continue to be the manufacturing partners of choice for pharmaceutical companies. We have started to see volume green shoots in Q3 compared to Q2. We also in-licensed novel products of Triple hair and Caregen in dermatology and metabolic segment to drive future growth.” Result PDF